Next 10 |
2024-07-21 07:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Bristol-Myers Squibb - Investors Are Too Long-Term Focused Bristol-Myers Squibb Is A Bargain Now AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings Dividend Roundup: Gold...
2024-07-19 04:57:22 ET Summary In this article, I review my investments in mid and large-cap value stocks since October 2023. The portfolio returned a 14% return, narrowly beating the S&P equal-weighted index, but underperforming the S&P 500. 4 out of 10 picks beating the ...
2024-07-16 13:01:00 ET Short percentage in S&P 500’s healthcare companies rose slightly at the end of June from May as biotechnology industry continued to emerge as the most shorted sector, while most other sectors saw meager change in interest from last month.... Read the ...
2024-07-13 10:10:44 ET More on CureVac BV, GSK, etc. Pfizer Opts To Move Forward With Once-Daily Danuglipron - Don't Hold Your Breath The Next Paxlovid Pfizer: Buy This Big Yielder On The Strong Pipeline Moderna rival CSPC cleared to study RSV shot in China ...
2024-07-12 08:41:47 ET More on CSPC Pharmaceutical, Moderna, etc. Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Mitsubi...
2024-07-10 10:14:24 ET More on OpenAI OpenAI models available to Microsoft Azure customers in China: report Microsoft, Apple ditch OpenAI seats amid antitrust scrutiny - report Musk drops lawsuit against OpenAI: report Read the full article on Seeking A...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
2024-07-09 04:07:54 ET More on Moderna Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) COVID infections could be seeing a summer s...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
2024-07-05 05:29:10 ET Summary Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...